\nThey cause infections in the lungs, urinary tract, wounds and bloodstream. Common hospital pathogens in this group include Escherichia coli<\/a> (E. coli), Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa.
\nCarbapenems are a powerful class of antibiotics used for serious infections. They are often the last line of defence.\u00a0
\nWhen bacteria become resistant to carbapenems, doctors are left with very few effective medicines.<\/p>\n
Key Findings of the ICMR Study<\/p>\n
The study was conducted by ICMR\u2019s antimicrobial resistance surveillance network across 20 tertiary-care hospitals between April 2022 and April 2025.\u00a0
\nMortality was consistently higher among patients with carbapenem-resistant infections across all four major pathogens. The relative risk of death was 1.16 to 1.43 times higher.\u00a0
\nMore than 61 per cent of Gram-negative infections in the study were carbapenem-resistant.\u00a0
\nExperts call carbapenem resistance a major threat to patient survival, especially in severe and bloodstream infections. However, they caution against treating resistance as an entirely independent cause of death.\u00a0
\nSeverity of illness, timing of treatment, source control and patient factors also shape outcomes. Resistance is best understood as an important marker of excess mortality.
\nThe study also points to healthcare-associated transmission, invasive devices, recent surgery, antibiotic pressure and gaps in infection prevention and diagnosis.\u00a0
\nAMR is the product of a complex interaction among these factors. It cannot be reduced to antibiotic overuse alone.<\/p>\n
The Hidden Economic Burden<\/p>\n
The study\u2019s cost figures are conservative. Researchers looked only at the cost of antibiotics available under the Jan Aushadhi scheme.\u00a0
\nThey excluded ICU charges, bed costs, diagnostics, procedures, supportive care and consultation fees.
\nEven on this narrow measure, antibiotic costs for resistant infections were 1.1 to 2 times higher. The true burden on patients, families and the healthcare system is likely far greater.<\/p>\n
A Signal, Not a Verdict, on Newer Drugs<\/p>\n
The antibiotic Ceftazidime-avibactam was linked to better outcomes in some resistant E. coli and K. pneumoniae infections, including bloodstream infections. Experts describe this as an important signal rather than proof of superiority.\u00a0
\nThe study was observational and could not fully adjust for disease severity, timing of therapy or resistance mechanisms.\u00a0
\nThe results reflect real-world treatment patterns in India, not a definitive drug ranking.\u00a0
\nThis underlines the need for better diagnostics to guide treatment instead of simply escalating to newer, broader antibiotics.<\/p>\n
Antibiotics Cannot Replace Infection Prevention<\/p>\n
More than 85 per cent of bloodstream infections in the study were healthcare-associated. This shows that Indian hospitals are relying on antibiotics to fix what is essentially an infection-prevention failure.
\nHospitals must place infection prevention and control at the centre of their AMR response.\u00a0
\nThis includes hand hygiene, prevention of device-associated infections, appropriate insertion and early removal of invasive devices, environmental cleaning, surgical infection prevention and surveillance of healthcare-associated infections.
\nAntimicrobial stewardship is equally vital. The answer to rising resistance is not stronger antibiotics.\u00a0
\nIt is to prevent infections, diagnose them quickly and use the narrowest effective antibiotic for the shortest appropriate duration.<\/p>\n
The Way Forward: An Integrated Response<\/p>\n
First, India must move from isolate-based surveillance to integrated surveillance that links laboratory results with patient outcomes, mortality and treatment.\u00a0
\nSecond, faster and more accurate diagnostics are needed to distinguish bacterial from non-bacterial illness and detect resistance early.\u00a0
\nThird, antimicrobial stewardship must become routine clinical practice, not an optional programme.\u00a0
\nFourth, infection prevention must receive as much attention as prescribing.\u00a0
\nFinally, India needs responsible access to newer antimicrobials, backed by stewardship, so these drugs remain effective when truly needed.<\/p>\n
Conclusion<\/p>\n
The ICMR study confirms that carbapenem resistance is a serious threat to survival and a heavy economic burden. India\u2019s AMR crisis cannot be solved by discovering a new antibiotic each time an old one fails.\u00a0
\nPreventing infections, diagnosing them early and preserving existing antibiotics must become the core of national health policy.<\/p>\n
Source: IE<\/a><\/p>\n Antimicrobial Resistance in India FAQs<\/p>\n Q1. What is causing antimicrobial resistance in India?+<\/p>\n Q2. Why is carbapenem resistance particularly concerning in India?+<\/p>\n Q3. What did the ICMR study reveal about antimicrobial resistance in India?+<\/p>\n Q4. How does antimicrobial resistance increase healthcare costs in India?+<\/p>\n Q5. How can India address its antimicrobial resistance crisis?+<\/p>\n Tags: Antimicrobial Resistance in India<\/a> mains articles<\/a> upsc current affairs<\/a> upsc mains current affairs<\/a> <\/p>\n
![\"Vajiram](\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2026\/09\/44ed6e64fbfcdba5f25c3789fd01d2339f65e0ca56f2ae6819609362177190d9.jpeg\"\/)
<\/p>\n![\"UPSC](\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2026\/09\/1788896787_691_SureShot.webp\"\/)
<\/p>\n